OUS

Get a grip on bone healing with MagnetOs™

NeedleGrip™ surface technology for osteoinductivity

NeedleGrip surface techonology

MagnetOs: a bone graft like no other

The one thing a surgeon can do right now to maximize fusion rates? Re-evaluate their selection of bone graft.

Surgeons can maximize clinical outcomes by making evidence-based decisions on bone graft selection.

MagnetOs is a synthetic next generation osteoinductive bone graft with a unique NeedleGrip surface technology that has shown favorable preliminary results vs. autograft in a prospective, multi-center, randomized, intrapatient controlled trial.

3 well-controlled Level I clinical studies

>25,000 patients treated worldwide. Kuros has a commercial & research footprint that spans 4 continents and covers 19 markets.

What are you basing your decisions on... today?

Mechanism of action through the NeedleGrip surface technology

NeedleGrip: Getting a grip on non-unions

MagnetOs is a bone graft like no other: it is osteoinductive thanks to its NeedleGrip surface technology, which means it grows bone without the need of added cells or growth factors. This surface technology provides traction for our body’s vitally important ‘pro-healing' immune cells (M2 macrophages).

This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft.

The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients, it means one thing: a more predictable fusion.

Pro-inflammatory

Promote inflammatory fibroblast proliferation.

Polarization

Phenotype changes accordingto the environment.

Pro-healing

Upregulate healing cells such as stem cells.

Demonstrates cells communicating

Differentiation

Stem cells differentiate into osteoblasts that lay down osteoid.

Demonstrates cells differentiating

Scan to learn about MagnetOs mechanism of action

MagnetOs propagates bone growth from the core

MagnetOs propagates new bone growth from the core as well as by creeping-edge repair in critically-sized long-span fusion sites, such as PLF.

MagnetOs

6 weeks

Islands of bone form in the center of the fusion bridge for MagnetOs.

12 weeks

Complete bridging of bone between the transverse processes.

26 weeks

Resorption and remodeling of the graft.

Autograft

Result: Complete bridging bone that is equivalent to autograft.

Histology images of an ovine instrumented PLF after 6, 12 and 26 weeks

Fuchsia = bone growth Black = MagnetOs Purple = fibrous tissue

Fuchsia = bone growth Purple = fibrous tissue

Taking fusion assessment a step further

MagnetOs forms strong consistent fusions

Results of an ovine instrumented posterolateral fusion at 12 weeks. These 3D-reconstructions of treated spines are based on micro-CT, manual palpation, X-ray, histology, and histomorphometry.

Grey regions = new bone + residual graft

MagnetOs

Autograft

Vitoss® BA2X

Fuchsia = bone Black = bone graft material

Purple = fibrous tissue

Clinical studies cannot discern bone, graft, and fibrous tissue because of an inability to obtain histological sections.

Novabone Putty® i-FACTOR Putty® FIBERCRAFT® BG Matrix

5mm

Black = bone graft material

MagnetOs versus autograft: a level 1 clinical trial

MagnetOs Granules was evaluated for posterolateral fusion in a prospective, randomized, controlled, multi-center clinical trial with intra-patient comparisons.

Study design

Single-/multi-level instrumented posterolateral fusion with intrapatient comparison of standalone MagnetOs Granules versus autograft (at least 50% iliac crest derived).

Demographics

• 91 subjects

• 128 levels

• Mean pre-operative ODI = 46

• 19% of subjects current smokers

Surgeons performing procedures were blinded until bone graft application.

CTs read by two independent, blinded spine surgeons.

One-year follow-up: Fusion by CT, ODI, adverse events (safety)

MagnetOs has achieved nearly twice the fusion rate of autograft in Level 1 clinical trial

Overall fusion rate of 79% for MagnetOs vs 47% autograft 79% 47%

Achieving successful fusions in the smoker population has always been incredibly challenging. However, MagnetOs demonstrated more than twice the fusion rate in this group compared to autograft.

Patient case study 1

Results from an ongoing prospective clinical trial†6

70-year-old female

Diagnosis: Spinal deformity

Radiographic Outcomes: The MagnetOs Granules side was fused at all four levels, whereas the autograft side was fused at two levels. The interbody was fused.

Procedure:

Four-level PLF at L1-L5 (with TLIF)

• Right side of subject: Autograft

• Left side of subject: MagnetOs Granules

Patient case study 2

67-year-old male

Diagnosis: Expected instability from decompressive surgery.

Radiographic Outcomes: The MagnetOs Granules side fused at three levels and the autograft side fused at two levels. Both interbody constructs fused.

Procedure:

Four-level PLF at L2-S1 (combined with TLIF)

• Right side of subject: MagnetOs Granules

• Left side of subject: Autograft

3D reconstructions at one-year follow-up.

Blue: MagnetOs Granules: Gray: Autograft; Light gray: Instrumentation.

Fine-cut CT scans at one-year follow-up.

Left: Coronal. Middle: Sagittal. Right: Axial

Fine-cut CT scans at one-year follow-up.

Left: Coronal. Middle: Sagittal. Right: Axial

3D reconstructions at one-year follow-up.

Blue: MagnetOs Granules: Gray: Autograft; Light gray: Instrumentation.

MagnetOs Granules MagnetOs Putty

MagnetOs Granules can be combined with autogenous bone, blood, PRP and/or bone marrow.

This is our original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology. It forms the foundation of all MagnetOs formulations and is the driver of its mechanism of action.

Available in: Volume (cc) Granule size (mm)

5 1 - 2

20 2 - 4

MagnetOs Putty can be combined with autogenous bone. MagnetOs Putty carrier is designed to maximize handling properties, so you can twist, tear and mold it into any shape desired before implantation and remain confident that it will stay in place and resist migration and irrigation.

Available in: Volume (cc) Dimensions (mm) Granule size (mm)

18 L x 8 W x 7 H 1 - 2

Want to see preparation and application of MagnetOs in an actual procedure? Watch this quick video!

Why choose MagnetOs?

MagnetOs is osteoinductive and osteoconductive: proven to grow bone without added cells or growth factors thanks to its unique NeedleGrip surface technology.

• Efficacy: MagnetOs achieved an overall fusion rate of 79% vs. 49% for autograft in a major level 1 clinical trial.

• Mechanism of action: triggers osteoinduction through the NeedleGrip surface technology

• Handling properties that minimize risk of migration and resists irrigation

• Safety: free of animal and human tissues

• Versatility: MagnetOs is a single product for the entire skeletal system, including spine, pelvis, extremities, cranial, mandible and maxilla

About Kuros Biosciences

MagnetOs is manufactured by Kuros Biosciences. The company is listed on the SIX Swiss Exchange under the symbol KURN and has a commercial & research footprint that spans three continents.

References:

[Distributor space]

kurosbio.com cs.international@kurosbio.com

Scan for more information:

Manufactured by Kuros Biosciences BV

Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands. MagnetOs and NeedleGrip are trademarks of Kuros Biosciences